Fritextsökning
Artiklar per år
Innehållstyper
-
Olerup klart för Kanada
Olerups kit för HLA-typning har godkänts av det kanadensiska läkemedelsverket.
-
Pengar till forskning utan djur
Idag träder ett nytt regelverk i kraft, som förbjuder försäljning av nya produkter som helt eller delvis har utvecklats med hjälp av djurförsök. Idag meddelas också att fem svenska forskargrupper får stöd för forskning kring alternativa testmetoder.
-
Analys av onkoproteiner i nanoskala
Cell Biosciences lanserar ett analys-kit för MEK- och ERK-proteinerna, som kan användas inom cancerforskningen.
-
Orexo mot nya marknader
Smärtbehandlingen Abstral har godkänts för försäljning i Frankrike och Spanien. Det ger Orexo rätt till en milstolpeutbetalning.
-
Bioinvent inleder fas II-studie
Bolagets blodproppspreparat ska testas på knäoperationspatienter.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
New CEO to Promedvi
Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Vitamin D is mental health aid
Vitamin D can help stave off the mental decline that can affect people in old age, a study suggests.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Danisco strengthens its IP team
Danisco's division Genencor has appointed a new Vice President of Intellectual Property Strategy and Chief IP Counsel.
-
Apoteket gets new vice CEO
The Swedish government company Apoteket has recently appointed a vice CEO.
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
BREAKING